We are proud to announce the launch of the next generation self-tonometer, the iCare HOME2.
iCare HOME2 provides unsurpassed ease of use and accuracy in monitoring real-world intraocular pressure behavior outside of the doctor’s office and clinical hours, supporting glaucoma management. Glaucoma is a chronic, progressive disease of the optic nerve. As intraocular pressure (IOP) is the only modifiable risk factor for glaucoma progression, disease management is centered around the reduction of IOP. Therefore, comprehensive and accurate information on peak IOPs and IOP fluctuation patterns is crucial.
Most patients can utilize iCare HOME2 simply by following the advice and guidance in the instruction materials, freeing up health care professionals’ precious time. iCare HOME2’s smart light guide helps the patient in positioning the device correctly and in making the measurements effortlessly and accurately, every time. It is now easier than ever for doctors to provide glaucoma management based on real-world IOP information, from finding the optimal medication and instillation schedule, to assessing the need for and effectiveness of surgery.
With the novel iCare PATIENT2 mobile app, the patients can follow their own IOP trends from an iOS or Android mobile device and send the IOP measurement results easily for healthcare professional’s review in the cloud based iCare CLINIC software. Using iCare HOME2 and PATIENT2, the patient can actively participate in the care process by providing valuable information to the healthcare professional. Patient motivation for medication compliance can improve, and knowledge of the real-time IOP levels provides daily reassurance.
For further information, please contact:
Business Line Director, Ophthalmic Home Products
Icare Finland Oy
iCare HOME2, PATIENT2 and CLOUD are currently available in EU and EFTA countries, Australia, Argentina, Bangladesh, Bahrain, Belarus, Canada, Colombia, Dominican Republic, Ecuador, Ethiopia, Georgia, Guatemala, Hong Kong, India, Israel, Kenya, New Zealand, Pakistan, Sri Lanka, Thailand, Turkey, Ukraine, UK and Vietnam.